Vivimed Labs Limited
NSE: VIVIMEDLABPharmaceuticalsTrade-to-trade true
Share price
₹7.25
+4.92% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
22
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹62 Cr
P/E ratio
—
P/B ratio
-0.3
ROCE
-65.2%
ROE
—
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Our sales figures for this company step down at Mar 2021 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
Our sales figures for this company step down at Mar 2021 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.
Room to re-rate, or risk of de-rating
It has no earnings, so there is no price-to-earnings to compare.
Whether growth justifies the valuation
It has no earnings to weigh the price against.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Vivimed Labs Limited — this one | 14%/yr | — | — |
| IOL Chemicals and Pharmaceuticals Limited | 2%/yr | 33.7× | ₹16.9 |
| Orchid Pharma Limited | 53%/yr | 346.5× | ₹6.5 |
| FDC Limited | 12%/yr | 17.2× | ₹1.4 |
| Novartis India Limited | -3%/yr | 50.7× | — |
| Gujarat Themis Biosyn Limited | -7%/yr | 97.0× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 130 of 130 on returns, 116 of 127 on growth, 128 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
It is losing money on the capital in the business, so there is no advantage to measure.
Whether its growth pays for itself
Yes — Over the last five years it made ₹45 crore of cash from the business, spent ₹30 crore on plant and equipment, and returned ₹51 crore to lenders and shareholders. It has not made a profit over 12 years.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
2 of 8 checks clear · 25%
Latest result
What the last results showed. Whether management kept its word is in Pro.
Results are expected soon.
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹62 Cr
- Prev close
- ₹7.25
- 52w High
- ₹29.4
- 52w Low
- ₹4.8
- Enterprise value
- ₹458 Cr
- Beta
- 0.3
- Price CAGR 1y
- —
- Price CAGR 3y
- 10.0%
- Price CAGR 5y
- -22.0%
- Price CAGR 10y
- -25.0%
Ratios
- Return on assets
- -23.4%
- PEG ratio
- —
- P/E ratio
- —
- P/B ratio
- -0.3
- EV / EBITDA
- —
- Industry P/E
- 37.6
- ROCE
- -65.2%
- ROCE 5y average
- -27.8%
- ROE
- —
- Debt / Equity
- —
- Interest coverage
- -43.0
- Dividend yield
- 0.0%
- ROE 3y average
- —
- ROE last year
- —
Annual P&L
- Annual revenue
- ₹70 Cr
- Annual profit
- -₹176 Cr
- Operating margin
- -218.0%
- Net profit margin
- -251.4%
- EBITDA margin
- -217.1%
- Sales growth 3y
- -27.9%
- Sales growth 5y
- -39.5%
- Profit growth 3y
- 14.0%
- Profit growth 5y
- —
- EPS
- ₹-21.3
- Sales growth TTM
- -40.0%
- Profit growth TTM
- -452.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹12 Cr
- Profit latest quarter
- -₹147 Cr
- YoY quarterly sales growth
- -53.1%
- YoY quarterly profit growth
- —
- OPM latest quarter
- -1169.0%
Balance Sheet
- Book Value
- —
- Face Value
- ₹2.0
- Total debt
- ₹397 Cr
- Total cash
- ₹1 Cr
- Borrowings
- ₹397 Cr
- Reserves / Equity
- -13.4
Cash Flow
- Operating cash flow
- ₹8 Cr
- Free cash flow
- ₹7 Cr
- FCF yield
- 4.9%
- Net cash flow
- ₹1 Cr
Shareholding
- Promoter holding
- 7.6%
- FII holding
- 1.6%
- DII holding
- —
- Public holding
- 90.7%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,749.70 | 33.1 | 4,19,812 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,361.00 | 83.4 | 2,48,505 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,594.75 | 78.3 | 1,74,770 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,115.85 | 22.9 | 1,11,306 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,002.45 | 99.0 | 1,08,195 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,296.80 | 29.3 | 1,04,765 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Dr Reddy's Labs | 1,175.60 | 30.5 | 98,125 | 0.67 | 435.6 | -68.7 | 8,099.8 | -5.5 | 13.0 |
| Vivimed Labs. | 6.80 | 56 | 0.00 | -147.1 | -2527.1 | 12.0 | -53.1 | -65.2 | |
| Median | 414.25 | 34.0 | 2,117 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37 | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 201 | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Material Cost | 7.76 | 11 | 5.30 | 8.93 | 7.91 | ||||||||
| Change in Inventories | 3.69 | -0.98 | 3.82 | -1.03 | 39 | ||||||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | 0 | 0 | ||||||||
| Employee Cost | 8.79 | 5.71 | 5.60 | 3.70 | 9.97 | ||||||||
| Other Expenses | 7.38 | 6.17 | 6.85 | 15 | 94 | ||||||||
| Operating Profit | -164 | -0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | -0 | -1 | -11 | -140 |
| OPM % | -444 | -0.93 | -18 | 3.06 | -74 | -37 | -2.58 | 2.88 | -9.64 | -1.31 | -4.61 | -68 | -1,169 |
| Other Income | 1 | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | ||||||||
| Interest | 9 | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 96 | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before tax | -268 | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | -1 | 0 | 0 | -3 | 21 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Net Profit | -266 | -16 | -20 | -16 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| EPS in Rs | -32 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2 | -18 |
| Diluted EPS in Rs | -0.65 | -0.64 | -0.85 | -0.85 | -17 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Expenses | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 182 | 129 | 222 |
| Material Cost | 58 | 33 | ||||||||||
| Change in Inventories | 2.09 | 41 | ||||||||||
| Purchases of Stock-in-Trade | 0 | 0 | ||||||||||
| Employee Cost | 28 | 25 | ||||||||||
| Other Expenses | 41 | 123 | ||||||||||
| Operating Profit | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -152 |
| OPM % | 16 | 17 | 28 | 18 | 14 | 1 | 3.70 | -3.30 | -100 | -22 | -11 | -218 |
| Other Income | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 6 |
| Exceptional items (within Other Income) | 0 | 0 | ||||||||||
| Interest | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 2.95 | 4 |
| Depreciation | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 26 |
| Profit before tax | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -176 |
| Tax % | 7 | 16 | 25 | 11 | 13 | -0 | 3 | 4 | -1 | -1 | 0 | 0 |
| Net Profit | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS in Rs | 8.90 | 10 | 26 | 9.44 | 6.95 | -13 | -8.67 | -8.16 | -40 | -5.48 | -3.85 | -21 |
| Diluted EPS in Rs | -3.74 | -21 | ||||||||||
| Dividend Payout % | 0 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- -26%
- 5 years
- -39%
- 3 years
- -28%
- TTM
- -40%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 14%
- TTM
- -452%
Stock price CAGR
- 10 years
- -25%
- 5 years
- -22%
- 3 years
- 10%
- 1 year
- —
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -227 |
| Borrowings | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 397 |
| Other Liabilities | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 567 |
| Total Liabilities | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
| Fixed Assets | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 386 |
| CWIP | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 181 |
| Other Assets | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 170 |
| Total Assets | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 951 | 921 | 753 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 140 | 154 | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -1.75 | 8 |
| Cash from Investing Activity | -107 | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 | -1 |
| Cash from Financing Activity | -42 | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 | -6 |
| Net Cash Flow | -8 | 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 | 1 |
| Free Cash Flow | 16 | 95 | -11 | -142 | 333 | -33 | 1,084 | 11 | 30 | -26 | -6.53 | 7 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 | 236 |
| Inventory Days | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 | 63 |
| Days Payable | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 | 263 |
| Cash Conversion Cycle | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 | 36 |
| Working Capital Days | 43 | 58 | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 | -1,468 |
| ROCE % | 11 | 12 | 22 | 9 | 7 | -3 | -1 | -3 | -52 | -11 | -8 | -65 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
1.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-03-31
the company's own loans / revolving facilities in default at period end (standalone filing)
388cr
2026-03-31
total loans / revolving facilities outstanding at period end, the base of loan_default_cr
388cr
2026-03-31
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
396inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Vivimed Labs Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Allopurinol API for tablets
- Bilastine API for tablets
- Chlorthalidone API for tablets
- Edoxaban API for tablets
- Empagliflozin API for tablets
- Packing materials
- Raw materials and consumables for pharmaceutical products
- Rivaroxaban API for tablets
Sells to
- Cipla · APIs / pharmaceutical intermediates
- Glenmark Pharmaceuticals Limited · APIs / pharmaceutical intermediates
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE526G01021
Plants
- Vivimed Labs Bidar Specialty Chemicals Plant
- Vivimed Labs Goregaon Mumbai Unit
- Vivimed Labs Haridwar Finished Dosage Plant
- Vivimed Labs Jeedimetla Phase III Formulation Plant
- Vivimed Labs Jeedimetla Phase V Plant
- Vivimed Labs Kashipur Finished Dosage Plant
- Vivimed Labs Kishlay Kashipur Plant
News impact
Big market events that reach Vivimed Labs Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 19 Sep 2018 | unspecified | ₹0.4 |
|---|---|---|
| 21 Sep 2017 | unspecified | ₹0.4 |
| 6 Apr 2016 | split | ₹0 |
| 24 Sep 2014 | unspecified | ₹3 |
| 24 Sep 2013 | unspecified | ₹3 |
| 21 Sep 2012 | unspecified | ₹3 |
| 26 Sep 2011 | unspecified | ₹2 |
| 9 Sep 2010 | unspecified | ₹1.5 |
Splits, bonuses & buybacks
- daily-prices repair: 4 rows from NSE's archive (replace 0, delete 1, insert 3), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2024-256 Sep 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.